These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 29629605)

  • 1. ECTRIMS/ACTRIMS 2017: Closing in on neurorepair in progressive multiple sclerosis.
    Kremer D; Küry P; Hartung HP
    Mult Scler; 2018 May; 24(6):696-700. PubMed ID: 29629605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS) - 7th Joint Triennial Congress (October 25-28, 2017 - Paris, France).
    Díaz N
    Drugs Today (Barc); 2017 Oct; 53(10):559-563. PubMed ID: 29286058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I).
    Fernández Ó; Álvarez-Cermeño JC; Arroyo-González R; Brieva L; Calles-Hernández MC; Casanova-Estruch B; Comabella M; de las Heras V; García-Merino JA; Hernández-Pérez MA; Izquierdo G; Meca-Lallana JE; Muñoz-García D; Olascoaga J; Oreja-Guevara C; Prieto JM; Ramió-Torrentà L; Rodríguez-Antigüedad A; Romero-Pinel L; Sanchez F; Téllez N; Tintoré M; Montalban X;
    Rev Neurol; 2012 Jun; 54(11):677-91. PubMed ID: 22627749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of trial design and patient heterogeneity on the identification of clinically effective therapies for progressive MS.
    Mills EA; Begay JA; Fisher C; Mao-Draayer Y
    Mult Scler; 2018 Dec; 24(14):1795-1807. PubMed ID: 30303445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease-modifying treatments for progressive multiple sclerosis.
    Comi G
    Mult Scler; 2013 Oct; 19(11):1428-36. PubMed ID: 24062415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.
    Nandoskar A; Raffel J; Scalfari AS; Friede T; Nicholas RS
    Drugs; 2017 May; 77(8):885-910. PubMed ID: 28429241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocrelizumab: its efficacy and safety in multiple sclerosis.
    Juanatey A; Blanco-Garcia L; Tellez N
    Rev Neurol; 2018 Jun; 66(12):423-433. PubMed ID: 29897610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACTRIMS-ECTRIMS 2002. Abstracts of the 7th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and 18th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. September 18-21, 2002. Baltimore, Maryland, USA.
    Mult Scler; 2002 Sep; 8 Suppl 1():S1-142. PubMed ID: 12371412
    [No Abstract]   [Full Text] [Related]  

  • 10. 'Progressive MS - macro views': The need for novel clinical trial paradigms to enable drug development for progressive MS.
    Zaratin P; Comi G; Leppert D
    Mult Scler; 2017 Oct; 23(12):1649-1655. PubMed ID: 29041866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function.
    Ontaneda D; Thompson AJ; Fox RJ; Cohen JA
    Lancet; 2017 Apr; 389(10076):1357-1366. PubMed ID: 27889191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel therapeutic options for multiple sclerosis.
    Curtin F; Hartung HP
    Expert Rev Clin Pharmacol; 2014 Jan; 7(1):91-104. PubMed ID: 24325127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in Multiple Sclerosis Neurotherapeutics, Neuroprotection, and Risk Mitigation Strategies.
    Abdelrahman A; Alvarez E
    Neurol Clin; 2024 Feb; 42(1):115-135. PubMed ID: 37980110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highlights From the 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
    Costello FE; Santos-Lang M
    J Neuroophthalmol; 2015 Jun; 35(2):e15-6. PubMed ID: 25768247
    [No Abstract]   [Full Text] [Related]  

  • 15. Targets of therapy in progressive MS.
    Lassmann H
    Mult Scler; 2017 Oct; 23(12):1593-1599. PubMed ID: 29041864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis.
    McCormack PL; Scott LJ
    CNS Drugs; 2004; 18(8):521-46. PubMed ID: 15182221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability.
    Kiselev I; Bashinskaya V; Baulina N; Kozin M; Popova E; Boyko A; Favorova O; Kulakova O
    Mult Scler Relat Disord; 2019 Apr; 29():130-136. PubMed ID: 30711878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of the novelties from the 2014 ECTRIMS-ACTRIMS Joint Congress, presented at the 7th Post-ECTRIMS Meeting (II).
    Fernandez O; Alvarez-Cermeno JC; Arroyo R; Brieva L; Calles-Hernandez MC; Casanova-Estruch B; Comabella M; Garcia-Merino JA; Ginestal R; Izquierdo G; Meca-Lallana JE; Mendibe-Bilbao MM; Montalban X; Munoz-Garcia D; Olascoaga J; Oliva-Nacarino P; Oreja-Guevara C; Ramio-Torrenta L; Romero-Pinel L; Rodriguez-Antiguedad A; Saiz A; Tintore M; Grupo Post-Ectrims GP
    Rev Neurol; 2015 Sep; 61(6):271-83. PubMed ID: 26350778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A patient with established primary progressive multiple sclerosis transitions to 'secondary' relapsing-remitting disease course following a fulminant demyelinating episode.
    Tutuncu M; Demirci NO; Özer F; Saip S; Kantarci OH; Siva A
    Mult Scler; 2011 Oct; 17(10):1262-4. PubMed ID: 21135019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.